Phase I dose-escalation drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with solid tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 May 2016
At a glance
- Drugs Sorafenib (Primary) ; Bevacizumab; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- 26 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 10 Sep 2014 Planned End Date changed from 1 Jan 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 16 Aug 2012 Additional lead trial investigator (Daniela E Matei) identified as reported by ClinicalTrials.gov.